Last reviewed · How we verify
NCT06942533: EXPARK
Effect of Visual Feedback From the SpiroGym Mobile Application
NA trial testing EMST with SpiroGym app in Parkinson Disease in 30 participants. Currently enrolling.
1 May 2026
Quick facts
| Lead sponsor | General University Hospital, Prague |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 May 2025 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 July 2026 |
| Sites | 2 locations across Czechia |
Drugs / interventions tested
- EMST with SpiroGym app
- EMST without SpiroGym app
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
- Breathing Exercises — all drugs for Breathing Exercises →
- Telemedicine — all drugs for Telemedicine →
Sponsor
General University Hospital, Prague
Who can join
Adults 40 to 80, any sex, with Parkinson Disease or Breathing Exercises. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The previous pilot study showed that two weeks of intensive expiratory muscle strength training (EMST) with SpiroGym was sufficient to significantly improve voluntary peak cough flow (PCF). The improvement was quantitatively comparable to that reported in other intensive EMST studies of longer duration. To explain this rapid improvement, we considered the potential contribution of SpiroGym's visual feedback. We assumed that real-time visual feedback increased training effort compared with conventional EMST performed without immediate feedback. The aim of this study is to evaluate the effect of visual feedback provided by the SpiroGym mobile application on performance during expiratory muscle strength training in patients with Parkinson's disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06942533
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other General University Hospital, Prague trials
Trials by the same sponsor.
- NCT07493928 — HPV After chemoRadioTherapy · recruiting
- NCT07495410 — Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FIT · NA · enrolling by invitation
- NCT06789978 — Rapid Prehospital ACcess to ECPR in Prague · NA · recruiting
- NCT06585332 — Handgrip and Respiratory Dysfunction in HD Patients. · completed
- NCT06816160 — TRU-Cut Biopsy in Tumor cHaracterisation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06942533 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by General University Hospital, Prague
- Last refreshed: 1 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06942533.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing